ARKG ARK Genomic Revolution ETF
CBOEETFAs of 2026-08-24 16:00
Why ARKG matters now
ARK Genomic Revolution ETF (ARKG) is a US etf in Financial Services. The latest InvestLog snapshot shows $48.01 with -2.91% on the session and $1.68B in assets/market value.
The latest indexable market news headline is "ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable" from Seeking Alpha.
ETF Profile
Updated 2026-08-24Net Assets
$1.56B
NAV
$49.49
Expense Ratio
0.75%
Holdings
10
Issuer
ARK
Asset Class
Equity
Avg Volume
3,200,088
Inception
2014-10-31
Sector Exposure
Top Holdings
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| TXG | 10X GENOMICS INC-CLASS A | 9.55% | $197.9M |
| TWST | TWIST BIOSCIENCE CORP | 9.25% | $191.8M |
| TEM | TEMPUS AI INC-CL A | 8.72% | $180.7M |
| PSNL | PERSONALIS INC | 6.21% | $128.8M |
| CRSP | CRISPR THERAPEUTICS AG | 6.09% | $126.3M |
| ABSI | ABSCI CORP | 4.93% | $102.3M |
| NTRA | NATERA INC | 4.00% | $83.0M |
| LLY | ELI LILLY & CO | 4.00% | $83.0M |
| ILMN | ILLUMINA INC | 3.96% | $82.2M |
| GH | GUARDANT HEALTH INC | 3.91% | $81.0M |
Latest News
Fund Info
Asset Type
ETF
Exchange
CBOE
Currency
USD
Issuer
ARK
Asset Class
Equity
NAV Currency
USD
The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.